Member Info for sadoldgit

I suppose it depends on what tactics he is using.

Hefty trade? Tis only 1.5 million. Over 3.2 billion shares in Sareum. People have an entry price and people have an exit price. At the moment it is good in that much trading will consolidate our SP price ie less violent swings. We are on the radar for sure. There are a plentiful supply of those who would like to get in for a little lower.
Regards

Great news, should cut down the waiting list at food banks.

Very interesting of the issue with regards to unreported trials. if MOD involvement in testing we would never get to know. All information is highly classified and protected. They have the ability to investigate whoever, they want, how they want and when they want. There is no exception.

I would add, in my opinion, with reports of the origins of the virus, The Wuhan Institute of Virology, the funding of Gain for Function by Fauci since 2017 ( info kept from White House) after being stopped/ outlawed by Obama in 2014. The presence of the PLA at Wuhan shortly before the outbreak, further recent reports of Chinese military involvement going back to 2012. 99% of the virus is Coronavirus the other 1% is'unknown'. This Covid 19 virus also has a series of 4 positive amino acids in a row. This just does not happen in nature. Opposite charges attract and similar charges repel. There is much more that will not bore you with.

In light of the above i feel the MOD will have much more knowledge of this and hence will to some extent have made investigations into. Using a virus in biological warfare has been mooted since 2012. There is documentation which claims to support this. The Chinese would not even allow investigations by the WHO and prevented their access for over a month. Forensically cleaned laboratories and 1000's upon thousands of electronic files deleted. Information that the military may have, is not always fully passed onto the ruling elite in government . Likewise in China you certainly will never get to hear the truth from a communist government. Bats and pangolins my ar5e. The Chinese still refusing to have external investigations, Even denying that Gain of Function was ever carried out at Wuhan.

All very strange when you consider predictions have been made by notable people, of an even worse pandemic to come in the near future.
The world is indeed a very complex sinister place.

Regards

Morning HBD. apologies for a little late getting back to you.
Sar have not ever had a surplus of money.
Sar for years had a market cap of 10 to 30 million. Money was raised by large share dilutions.
To a large pharma irrespective of type of drug they have a pharma will display a little more than a passing interest. Yes, they may will be in discussions. But as Sar are a very small company, with a very small market cap, companies will only pick it up for next to nothing. They to an extent control the deal. He who has the big bucks dictates. You can be sure of that.

Recently, with our endeavours with regards to 1801 and covid in particular and a novel form of investment from high net worth individuals the market cap is now over 250 million.
A large pharma could pursue his point of no guarantee that any of the compounds will work. Yes, the compounds are new, novel even.

Bare in mind that we have raised circa 3.5 million and should we raise another 1.5 million , we have then demonstrated the ability to raise 5m which then opens the door to a further 30 million.

With this money Sareum ( subject to successful trial) could take their SDC 1801 molecule just for the purpose of Covid 19. Up front contracts with our government within a 12 month period you would expect to exceed 500 million income and most likely, more should 1801 be used for more than just down regulate the cytokine storm.

This is Covid 19 0nly and no other indication for our 1801 imunotherapy. We are now a company with an income, and kudos of not only having the best, but also the least toxic treatment for covid on planet Earth at this time.

Our market cap at least now at this point I would estimate at 4 billion. A very modest and I will say pessimistic approach based on 8 times annual turnover. Note this does not take into effect demand for compound outside the UK. The turnover will have a substantial increase on 500 million a year as will the market cap.

The point I make, apologies for being long winded. Sareum can now sit at the negotiating table completely in charge. Sareum now have options, having these options, has phenomenally increased not only their status, but also their negotiating power. Effectively, it will place Sar in the driving seat. For a total buyout at this stage, I would say the 13 billion recent deal would pale into insignificance.

The time period for this stage I would guess would be after stage 1 and 2 trials with fast track into treatment. 100 days, 7 to 14 days announcement of Agile. a further 60 day period for government contracts to be drawn up and filled. 167 to 174 days

5 and a half to 6 months to be in the driving seat with significant market increase when certain hurdles have been overcome and continuing success of compound.

These are just my thoughts on this. Oddly it does tie in with regards to timeframe of a takeover postulated likely to happen by other long term holders here.
Regards

Montyboz you are certainly not alone in that comment.

No option but to see how it pans out.

Remember historically all of our compounds have had excellent ADME properties. ie absorption, distribution, metabolism and excretion all with very little toxicity. CHK1 SRA737 will verify this in clinical trial. Aurora FLT+3, 1801 and 1802 in preclinical.

Regards

Mafuta, That thought has crossed my mind too. It will certainly ruffle a few feathers.
£3 billion would not seem unreasonable for 1801 alone in upfront payment and peanuts in comparison, to the cost to the world economy.
I have a feeling that Sareum may finance this themselves. Fast track into treatment. 100 million 12.5 mg per day minimum stocks. 10 pounds per tablet it would work out half the price of the ruthless US pharma want to glean from their useless Baricitinib. As I said before, it is not fit as i see it to be in the same room. There are those that disagree with my view on this, one of which has sold a large chunk of their shares in the past month. Negative tendencies all of a sudden just after a peak in SP

There are interested parties of that we can be sure. The silence is deafening.

Regards

stevebru.
My opinion and input.

Sareum has two Tyk2 Jak1 inhibitors. SDC 1801 and 1802 .
Due to the increased selectivity of Tyk2 over Jak2 it was postulated by Tim Mitchell that our SDC1801 could prove beneficial for the treatment ( especially down regulation of the cytokine storm ).

Early investigations indicate confirmation of down regulation in preclinical studies ie murine testing and modelling.
We await news on acceptance/entry to Agile platform, phase1 trial and fast tracked ( should this be an option that Sareum choose to take).

Both SDC1801 and 1802 can be administered via the intravenous or oral route. Oral route, more difficult to achieve as problems with how the compound is absorbed into the body. Look up LADMET.

The compound needs a carrier. The carrier and the compound passes through the intestinal tract, it is subject to stomach acids and a vast number of problematic phases that would not be otherwise encountered via the intravenous route.

We have developed a compound subject to manufacture, which can be taken orally. The purpose is to down regulate the cytokine storm. Much quicker to take an, oral bioavailability treatment either in a tablet of capsule than intravenously. No need 4 hr appointment at hospital. Reduced workload for our NHS staff and reduced costs.

Citizen79 )posted he had either dreamed, or came to the idea of a one a day tablet for the treatment of covid 19. Not taken overly serious, at the time.

We will now look at our competitor Baricitinib. Baricitinib is a Jak1 Jak 2 kinase inhibitor. Jak2 is associated with severe side effects and hence the NDA in the US have issued dreaded black box warnings. It was only allowed emergency use administration (EUA) It is not allowed by the NDA to be administered on its own.

Our Tyk2 Jak1 has no associated severe side affects. No toxicity issues were observed at 30 times treatment rates. Difficulty was experienced in reaching a maximum tolerated dose.

The idea of the orally taken compound for effective treatment of Covid had prompted investigations. In this aspect, to downregulate the cytokine storm that so far in models proved. Not proved effective in innate immune ie lung damage, pneumonia, due to fault with testing.

Baricitinib cannot be used in the true sense as a therapeutic treatment as is for EUA only due to severe side affects.

Should our SDC1801 continue and have the safety confirmed in stage one trials then there exists the probability that it can not only be used in the down regulation of the Cytokine storm but also in the prevention of. Tell me I am wrong.

In this case no need for vaccines,

A once a day pill, now becoming by the day more and more likely.

All subject to the medical profession of course and phase 1 trials.
Not sure big pharma's will like.

Regards

We now have the Columbian variant, only 16 people detected with it.

No indication of it spreading they state. Then how did 16 people become infected?

The government have a duty to protect its inhabitants. All possible routes as a form of prevention must be explored.
That is vaccines, wearing of masks and a suitable, effective treatment for those that develop severe symptoms.

Anti virals are not the be all and end all, they have limitations becoming less and less effective when the virus mutates. I do hope in this context, that Boris the buffoon is not relying on Demaxathone.

I remember Citizen79's post a while ago with the inferred SDC1801, pill a day to keep the covid away.

This I think is not as absurd as some may have thought..
Since we can down regulate the cytokine storm, we can argue that we can also prevent a cytokine storm by definition.

In this situation, by using down regulation of the cytokine storm and therefore control of it, it should be conceivable that this will allow our own immune system to develop an immunity to the particular strain of Covid 19.
Vaccines work by teaching our immune systems to identify and respond against unwanted germs and viruses ( normally by using an inert or deactivated form of a virus or germ)
if our immune system can utilise a vaccine, it should follow reason that our immune system can, also recognise and develop an ability, to destroy the virus in the absence of a cytokine storm.
In effect we could take it as far to say, we would not require a vaccine

I virion can produce i billion virions in a 24 hr period.

We have both an innate immune system and also an adaptive immune system.
The adaptive ( also known as acquired immune) system.

The innate immune system works to fight off pathogens before they can start an active infection. For some cases, the innate immune response is not enough, or the pathogen is able to exploit the innate immune response for a way into the host cells. In such situations, the innate immune system works with the adaptive immune system to reduce the severity of infection, and to fight off any additional invaders while the adaptive immune system is busy destroying the initial infection.

More info on this can be explained better than I can from link below

https://www.khanacademy.org/test-prep/mcat/organ-systems/the-immune-system/a/innate-immunity

Enough drivel from me, but thoughts and comments most welcome.

Regards

You are very much of the same opinion as myself on the Corona virus Thoth. Fears exist of serious killer mutation evolving soon.
A very recent article below.

https://www.msn.com/en-gb/health/medical/next-covid-variant-could-kill-one-in-three-people/ar-AAMLabW?ocid=msedgdhp&pc=U531
That must put at least another billion on the market cap as we stand now.

My understanding of the virus origins are laboratory made under gain of function and spliced with a very nasty other virus.

Regards

There is a an attachment below which you may find interesting which relates to Sierra's Momelotinib. It does look promising for them, which must be good for not only them of course, but us too.. 6 months before results expected to come through ie ist quarter of 2022.

http://www.sierraoncology.com/wp-content/uploads/2021/06/2021.06.02-SRRA-Corp-Presentation.pdf

Nothing wrong with critical thinking Steadydanny. There is just so much, we do not know, or have not been supplied all or the correct information.

Regards

Certainly food for thought there Steadydanny.
SRA has a fantastic pedigree. Developed alongside ICR and much to do with Michelle Garrett.
An abstract from June 2017:-

Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials.

Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an announcement made today by Sierra Oncology, Inc. reporting on the initial progress of the two ongoing Phase 1 trials of the Chk1 inhibitor, SRA737. The full announcement can be found on Sierra Oncology's IR website*.

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.

The SRA737 Phase 1 monotherapy trial has advanced through six single patient dose cohorts of 20, 40, 80, 160, 300 and 600 mg/day, administered under a continuous daily oral dosing regimen in 28-day cycles. Dose escalation will continue until a maximum tolerated dose (MTD) is reached, in parallel with ongoing Cohort Expansion enrolment.

Preliminary observations from the ongoing monotherapy study are as follows:

• SRA737 has been very well-tolerated to date: No Grade 2 or higher SRA737-related adverse events have been reported. No dose-limiting toxicities have been observed and an MTD has not been reached.

Note the ' no dose limiting toxicities have been observed' and maximum tolerated dose not been reached.

From 2018 :-
SRA737 Combination with Immuno-Oncology

During its Program Update in February, Sierra presented preclinical data providing evidence of synergy between SRA737 and immune checkpoint blockade. Sierra is currently designing a clinical study for this combination, which potentially could be submitted to regulatory authorities in the fourth quarter of 2018.

Interesting this Immuno- Oncology.

Interesting also is our CHK1 with regards to treatment of HGSOC ( high grade serious ovarian cancer)
see the link
https://www.prnewswire.com/news-releases/sierra-oncology-reports-preclinical-efficacy-for-chk1-inhibitor-sra737-in-treatment-refractory-ovarian-cancer-models-at-the-eortc-nci-aacr-symposium-300750660.html

All very impressive and lack of development has caused us to forget just how ' more commercially viable' SRA737 is.

I am thinking the stars are aligning for a deal of some sort to progress SRA737. If they do not use it they lose it along with a whole heap of costly research and investment.

Into August next week and the clock is ticking very fast. Deals are not done overnight. Plans in whatever shape of form will be in progress now ( my uptake of situation). I would estimate on commencement of development and trials, circa 100 million at least on market cap circa 3p per share increase. The market is huge and much left untouched with no competitors.

There is just so much potential in combo therapy with CHK1.

Regards

Only thing l would say is over one and a half times more buys shown against sells ie nearly 12 million sells v over 19 million buys. Only 3.5% up. Total volume shows just over 40 million, ie 9 million more than shown as traded.

That was very well picked up by you Zylo.

Regards

Tina Turner,
Prefer 'Simply the Best' and most likely will prove to be just that.
Regards

Ahfam 3 ,good morning, it just gets better here.

Very good, Jak1 and Tyk2 both inhibit IL-6 but need work in tandem. IL-23 leading to differentiation of Th-17. IL-10 required as precursor, interferon alpha,beta and gamma inhibited by Jak 1 and Tyk2 but signal via different STATS. Tumour necrosis factor alpha and granucyte macrophage colony stimulating factor controlled by Tyk2 Jak1. All the important controls there at the very least to down regulate the cytokine storm l believe.

The added advantage of no to very little toxicity issues as we understand so far. Human trials will confirm this.

Can see no reason for 1801 not to be used as a preventative of a cytokine storm if toxicity confirmed to be inline with current expectations.

Looking forward to next week.

Regards

Good morning Mafuta, we should easily pass the long awaited 10p. I would reckon give or take a bit, double figures from now on.

Regards and a great day for all.

Fairly busy at work so not much time to look here today. I did note at around 10 to 10.30 approximate volume 32 million against combined buys v sells ( a few hundred thousand more buys than sells) at 24 million. Indicative to me of quite a bit of activity going on in background. It were around this time I believe the SP peak of the day.

A few sells or buys from this board will make very little difference to the market cap or SP.

I feel pretty confident we will nudge 10p tomorrow or Monday. There is so much more interest here since the HNWI's came aboard.

News awaits us on many fronts.

Regards to all.

Mafuta,goodmorning. I believe Sierra are well aware of the worth of the Chk1. In an early statement with regards to funding they stated SRA 737 may prove to be more commercially viable than Momelotinib. Not long afterwards down came the for sale sign.

CHK1 not brilliant on it's own. I would hazard a guess this is due to cancer cells not having a programmed cell death (apoptosis). It is only when chemotherapy or similar is given which kills the cancer cells, that the cancer cells then divide rapidly ( normally mitosis ie splitting into two) and multiply rapidly.

The checkpoint kinase inhibitor prevents regrowth by cycle arrest by TP53 inhibition. TP53 is required in many cancer cell cycles to reproduce. Hence, very effective against many, but not all cancers, when used in combination. Very good ADME too.
Regards

Sorting out. Rebster thanks for that! God find. Settles things very nicely.

Regards